News

OvaScience and Millendo Therapeutics will merge in an all-stock deal to push forward Millendo’s lead candidates livoletide (AZP-531) and nevanimibe (ATR-101) for the treatment of Prader-Willi syndrome and Cushing’s syndrome, respectively. An investor group that includes New Enterprise Associates, Frazier Healthcare Partners, Roche…

Recorlev (levoketoconazole) safely and successfully reduces the levels of cortisol in patients with endogenous Cushing’s syndrome, according to top-line results of a Phase 3 clinical trial. Cushing’s syndrome occurs due to abnormally high levels of cortisol, mainly caused by prolonged exposure to cortisol-like steroid medications and less commonly by…

A test using betamethasone — a corticosteroid that causes the pituitary gland to stop producing ACTH – can accurately predict short- and long-term remission in Cushing’s disease patients who have had pituitary surgery, a retrospective study reports. The research, “An early post-operative ACTH suppression test can safely predict short- and long-term…

Korlym (mifepristone) is effective for the treatment of ectopic Cushing’s syndrome patients, with survival rates comparable to patients who undergo bilateral adrenalectomy (removal of the adrenal glands), new research shows. The study, “Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome,” was published in the journal…

American and Dutch patients with Cushing’s syndrome have different ways of interpreting the same items on a disease-specific quality-of-life (QoL) questionnaire, research shows. The study, “Assessing Differences in How the CushingQoL Is Interpreted Across Countries: Comparing Patients From the U.S. and the Netherlands,” was published in…

Metformin, an oral type 2 diabetes medicine, can promote cell death in tumors that cause Cushing’s disease and reduce the excessive production of the adrenocorticotroph hormone (ACTH) that underlies it, a study in mice cells reports. These findings suggest that metformin, a tablet, may offer a new way of treating…

Salivary cortisol levels can be used to diagnose Cushing’s syndrome with relatively high reliability, but each test center should establish its own measurement limits depending on the exact method used for the test, a study from Turkey shows. Researchers, however, caution that late-night salivary cortisol measurements in clinical practice…

Transsphenoidal surgery, a minimally invasive surgery to remove tumors in the pituitary gland, is safe and effective to treat Cushing’s disease, a 20-year history of cases in a Belgian hospital shows. The surgery resulted in high remission rates (83%) in patients. It was also found…

Treatment with metyrapone rapidly reduces cortisol levels in Cushing’s syndrome patients and keeps them low over the long term, a real-life study shows. The study, “Metyrapone treatment in Cushing’s syndrome: a real-life study,” was published in the journal Endocrine. Cushing’s syndrome is a condition where patients have too much cortisol…

Patients with Cushing’s disease whose pituitary tumors bear mutations in the USP8 gene are more likely to experience recurrence, and develop them sooner after surgery, a new study shows. The study, “The USP8 mutational status may predict long-term remission in patients with Cushing’s disease,” was published in the journal Clinical…